primary%20biliary%20cholangitis
PRIMARY BILIARY CHOLANGITIS

Primary biliary cholangitis (formerly primary biliary cirrhosis) is a chronic, progressive, autoimmune, cholestatic liver disease more common in middle-aged women. It is characterized by destruction of small to medium bile ducts leading to cholestasis and frequently, end-stage liver disease.
Diagnostic features are chronic biochemical cholestasis, presence of antimitochondrial antibodies and the characteristic liver biopsy findings.


 

Introduction

  • Primary biliary cholangitis (PBC) is an autoimmune disease of a chronic and progressive nature, characterized by destruction of small to medium bile ducts, leading to cholestasis and frequently, end-stage liver disease
    • Diagnostic features of PBC are the chronic biochemical cholestasis, presence of antimitochondrial antibodies (AMA) and the characteristic liver biopsy findings
  • Suggested to have environmental and/or genetic factors affecting its development
  • PBC is more common in Northern Europeans and the majority of the patients are middle-aged women
    •  Men with the disease are more likely to develop hepatocellular carcinoma (HCC)

Signs and Symptoms

Fatigue

  • The most common symptom seen in 50-78% of patients
  • Associated with depression, obsessive-compulsive disorder and sleep disturbances
  • Symptom does not correlate with severity of liver disease

Pruritus

  • Prevalence rate is 20-70% in patients with PBC
  • A circadian rhythm may be noted with worse symptoms at night
  • May be so severe as to cause severe emotional disturbance
  • May be present even in patients with good liver function
  • Declines in severity with time from diagnosis

Jaundice

  • Present in 10-60% of patients due to cholestasis

Right Upper Quadrant Pain

  • Occurs in 8-17% of patients
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Chronic pancreatitis patients taking antioxidants (AO) supplementation show a sustained increase in blood levels of AO, but no additional benefit is seen on endocrine and exocrine functions, markers of fibrosis, oxidative stress (OS) and inflammation, nutritional status, pain, and quality of life (QOL) when compared with those on placebo, according to a study.
Elvira Manzano, 06 Feb 2020
Neither sleep quality nor step count had a bearing on length of hospital stay (LOS) following bowel surgery in patients with inflammatory bowel disease (IBD), according to researchers at the recent AIBD 2019 Meeting.

Stephen Padilla, 27 Jan 2020
Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.
Roshini Claire Anthony, 4 days ago

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.